LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 83.89% | 81.48% | 78.30% | 7.74% | -54.54% |
| Total Depreciation and Amortization | 7.20% | 16.06% | 14.05% | 4.21% | 9.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.99% | -71.28% | -77.32% | 371.97% | 287.04% |
| Change in Net Operating Assets | 23.39% | -125.79% | -224.37% | -281.20% | -296.42% |
| Cash from Operations | 67.62% | 29.42% | 31.67% | -152.86% | -528.67% |
| Capital Expenditure | -2,144.18% | -854.27% | 78.16% | 128.72% | 95.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -125.46% | -96.54% | -162.35% | -1,581.25% | -155.33% |
| Cash from Investing | -1,069.99% | -824.01% | 26.43% | 105.19% | 71.41% |
| Total Debt Issued | -50.21% | 6.43% | 28.52% | 7.43% | 421.94% |
| Total Debt Repaid | 50.71% | 77.02% | 99.19% | -33.90% | -202.26% |
| Issuance of Common Stock | -13.03% | -31.80% | -82.62% | 248.29% | 160.90% |
| Repurchase of Common Stock | 99.97% | 99.97% | 99.97% | 99.97% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.04% | 8.04% | 12.57% | -204.59% | -96.46% |
| Cash from Financing | -19.20% | 3.11% | -42.35% | 130.23% | 302.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 259.86% | -174.07% | -402.71% | 100.02% | 74.59% |
